Latest Biotechnology Capital Management News

Page 1 of 1

Nexalis Therapeutics Links Director Fees to Phase 2 Trial Milestones with Share Rights

Nexalis Therapeutics has issued share rights to directors in lieu of fees, with vesting contingent on successful Phase 2 clinical trial completion, aiming to conserve cash for ongoing drug development.

Ada Torres

14 July 2026

Top